The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results of the Phase III APHINITY Trial in HER2-Positive Breast Cancer

Gunter von Minckwitz, MD, PhD
Published Online:7:23 PM, Wed July 5, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses results from the large phase III APHINITY trial, which explored the addition of pertuzumab (Perjeta) to adjuvant trastuzumab and chemotherapy for patients with HER2-positive early breast cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.